Ginkgo Bioworks Holdings, Inc.
DNA
$8.55
-$0.62-6.76%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 237.42M | 227.04M | 217.95M | 184.34M | 208.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 237.42M | 227.04M | 217.95M | 184.34M | 208.70M |
| Cost of Revenue | 47.39M | 44.55M | 41.54M | 36.46M | 40.83M |
| Gross Profit | 190.02M | 182.50M | 176.41M | 147.88M | 167.87M |
| SG&A Expenses | 215.09M | 236.34M | 249.43M | 279.17M | 307.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 5.06M | -1.25M | -1.25M | -1.25M | -5.24M |
| Total Operating Expenses | 626.07M | 703.70M | 754.44M | 858.75M | 897.55M |
| Operating Income | -388.65M | -476.65M | -536.49M | -674.42M | -688.86M |
| Income Before Tax | -472.50M | -547.51M | -651.54M | -897.68M | -853.93M |
| Income Tax Expenses | -422.00K | -479.00K | -352.00K | 1.00K | -122.00K |
| Earnings from Continuing Operations | -472.08 | -547.03 | -651.19 | -897.68 | -853.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -472.08M | -547.03M | -651.19M | -897.68M | -853.81M |
| EBIT | -388.65M | -476.65M | -536.49M | -674.42M | -688.86M |
| EBITDA | -323.13M | -413.63M | -476.28M | -610.32M | -624.44M |
| EPS Basic | -8.98 | -10.62 | -12.90 | -18.03 | -17.39 |
| Normalized Basic EPS | -4.13 | -5.22 | -5.94 | -7.64 | -7.99 |
| EPS Diluted | -8.99 | -10.63 | -12.92 | -18.05 | -17.41 |
| Normalized Diluted EPS | -4.13 | -5.22 | -5.93 | -7.64 | -7.98 |
| Average Basic Shares Outstanding | 211.67M | 207.54M | 203.16M | 199.69M | 196.66M |
| Average Diluted Shares Outstanding | 211.68M | 207.57M | 203.23M | 199.75M | 196.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |